MedTrace Logo

Preeclampsia Ratio (sFlt-1/PlGF)

NCT03289611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-03-10

No results posted yet for this study

Summary

The aim of the PRECOG study is to determine in a prospective interventional randomized study whether the implementation of a predictive test based on the sFLT-1/PlGF ratio improves perinatal care and reduces costs, in patients with suspected preeclampsia before 35 weeks of gestation.

Conditions

Interventions

BIOLOGICAL

sFlt-1 / PlGF ratio

* Ambulatory management if sFlt-1 / PlGF ratio is below 38 * usual management if sFlt-1/PlGF is between 38 and 85. * If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean GUIBOURDENCHE, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2020-08-27
Completion
2020-08-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03289611 on ClinicalTrials.gov